AZD2811 for Small Cell Lung Cancer (TAZMAN Trial)

"This medical trial is no longer recruiting patients, as the last update was on September 9th 2022. If you are hoping to get involved in other clinical trials, there are 1577 studies involving small cell lung carcinoma and 1534 triasl researching AZD2811 that have open enrolment procedures."

"Currently, 6 locations are accepting participants for this clinical trial. These include Montreal, Boston and Houston as well as other cities in proximity to those three. To minimize the need for travel, we recommend selecting a site near your location if you choose to enroll."

"AZD2811 is regularly administered to individuals suffering from Hodgkin's disease, yet can be prescribed for additional severe illnesses such as malignant pleural mesothelioma and advanced head/neck cancer."

"At present, there are 1,534 ongoing studies for AZD2811 with 442 of them in the advanced Phase 3. In addition to Shanghai's extensive involvement in these trials, 79345 other sites across the globe are conducting research on this medication."

"This research study is no longer accepting participants. It was originally published on February 23rd 2021 and last updated September 9th 2022. Fortunately, there are plenty of other clinical trials seeking individuals with small cell lung carcinoma; 1577 studies in total, as well as 1,534 for AZD2811."

"This medication has been assessed to have a safety rating of 2 out of 3 given that it is in the Phase 2 trial stage and there exists some evidence attesting to its security but no proof yet for efficacy."